Connect your AI

BioLife Solutions BLFS Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

AzentaAZTA

——

LeMaitre VascularLMAT

——

Other financials

Income statement

Revenue$27.5M+24.7%

Gross profit$17.5M+18.2%

Operating income$27.0K+105%

Net income$1.2M+365%

EPS (diluted)$0.02—

Balance sheet

Cash & equivalents$22.8M-65.9%

Total debt$17.4M-35.6%

Total equity$372.2M+5.6%

Total assets$400.9M+1.5%

Cash flow

Operating cash flow-$491.0K-128%

CapEx$167.0K-4.6%

Free cash flow-$658.0K-142%

Valuation

Market cap$1.34B+33.1%

Enterprise value$1.34B+38.1%

P/S13.5×+0.6×

Profitability

Gross margin66.9%—

Operating margin-16.7%—

Net margin-68.7%—

FCF margin-15.9%+18.7pp

Returns & leverage

Return on equity-14.5%-4.7pp

Debt / equity0×0.0×

Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is BioLife Solutions's available for sale securities debt securities current?: BioLife Solutions (BLFS) reported available for sale securities debt securities current of $58.17M in Q1 2026.
How has BioLife Solutions's available for sale securities debt securities current changed year-over-year?: BioLife Solutions's available for sale securities debt securities current increased by 168.9% year-over-year, from $21.64M to $58.17M.